Pharming Group NV
AEX:PHARM
Pharming Group NV
Total Liabilities
Pharming Group NV
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Total Liabilities
$222.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
21%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Total Liabilities
€63.4m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
20%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Total Liabilities
$626m
|
CAGR 3-Years
40%
|
CAGR 5-Years
45%
|
CAGR 10-Years
17%
|
|
|
argenx SE
XBRU:ARGX
|
Total Liabilities
$1.1B
|
CAGR 3-Years
50%
|
CAGR 5-Years
12%
|
CAGR 10-Years
61%
|
|
|
Merus NV
NASDAQ:MRUS
|
Total Liabilities
$129m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
32%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Total Liabilities
$53m
|
CAGR 3-Years
36%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Total Liabilities?
Total Liabilities
222.9m
USD
Based on the financial report for Dec 31, 2025, Pharming Group NV's Total Liabilities amounts to 222.9m USD.
What is Pharming Group NV's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
21%
Over the last year, the Total Liabilities growth was 25%.
